A team of scientists has developed a streamlined method for the automated production of lung organoids—miniature, lab-grown structures that replicate the cells of real lungs. This breakthrough could transform how treatments for lung disease are developed, enabling early-stage drug testing without relying on animal models.
In the future, patients might even have personalized organoids grown from their own tissue to test potential treatments in advance.
“The best result for now—quite simply—is that it works,” said Professor Diana Klein of the University of Duisburg-Essen, first author of the study published in Frontiers in Bioengineering and Biotechnology.
“This shows that lung organoids can, in principle, be produced automatically. These complex structures better mimic in vivo conditions than conventional cell lines, making them an excellent model for disease research.”
Klein added that the organoids could be used for high-throughput testing of potential therapies. “We can determine which drugs are effective and at what concentrations. This could accelerate the development of targeted treatments and even predict patient-specific reactions to radiotherapy or other therapies.”
Stem Cells Step Up
Lungs are intricate organs, making it difficult to model them in the lab. Lung organoids have long been seen as a promising solution, but manual production has been slow and labor-intensive.
“We start with stem cells and multiply them in plastic dishes,” explained Klein. “Once grown, the cells are detached and prompted to form small aggregates in anti-adhesive dishes. These aggregates, called embryoid bodies, are then treated with growth factors found in lungs or during lung development, which transform the cells into various lung cell types.”
The team cultured embryoid bodies in a specially designed tank with a stirring membrane and growth medium, while a control group was grown on conventional plates. After four weeks, the organoids were analyzed using microscopy, immunofluorescence, immunohistochemistry, and RNA sequencing.
Both sets of organoids developed lung-like structures, including airways and alveoli. RNA sequencing confirmed the presence of epithelial and mesodermal lung cells. Differences emerged in cell proportions: manually produced organoids had more alveolar cells, while bioreactor-grown organoids were larger but contained fewer alveolar spheres.
Scaling Up Research
The bioreactor’s ability to produce more organoids with less manual labor could be a gamechanger for lung disease research. However, further optimization is needed to improve organoid fidelity and better mimic in-body conditions.
“Organoids still lack some key components, like infiltrating immune cells and blood vessels,” Klein said. “We don’t have blood flow, so conditions are relatively static. But for patient-oriented drug screening, this may not be necessary if we can still gain insight into cellular responses.”
Klein emphasized the need for robust, scalable protocols. “Optimizing bioreactor design, selecting appropriate cell types, and fine-tuning growth conditions are all essential. There’s still a lot of work to be done, but we’re making progress.”
Related topic：
